Acute Migraine Treatment Market Report 2024

The acute migraine treatment market size has grown rapidly in recent years. It will grow from $2.35 billion in 2023 to $2.6 billion in 2024 at a compound annual growth rate (CAGR) of 11%. The increase during the historical period can be linked to the rising number of migraine cases, the expansion of specialty clinics, heightened funding for migraine research, an increase in clinical trials, and greater use of preventive medications.

The acute migraine treatment market size is expected to see rapid growth in the next few years. It will grow to $4.0 billion in 2028 at a compound annual growth rate (CAGR) of 11.3%. The anticipated growth in the forecast period is driven by the rising incidence of migraines, increased investment in migraine research, a higher demand for non-invasive treatment options, a preference for fast-acting relief solutions, and a stronger focus on patient-centered drug development. Key trends during this period include technological advancements, the adoption of neuromodulation devices, personalized medicine, telemedicine, and improved diagnostic tools.

The growing pressure at work is anticipated to drive the expansion of the acute migraine treatment market in the future. Work pressure encompasses the mental, emotional, and physical strain that employees experience due to job demands and challenges. Factors contributing to increased work pressure include tight deadlines, insufficient resources and support, poor work-life balance, unclear job roles, interpersonal conflicts, and organizational changes. Acute migraine treatments for high work pressure involve managing symptoms that may be triggered or worsened by stressful work conditions. For example, Mental Health America reported in 2023 that about 81% of workers felt that workplace stress impacted their mental health, up from 78% in 2021. As a result, rising work pressure is fueling the demand for acute migraine treatments.

Leading companies in the acute migraine treatment market are focused on developing innovative solutions, such as nasal sprays, to improve the effectiveness and convenience of migraine relief. Migraine nasal sprays administer medication through the nasal passages, offering the benefit of rapid absorption and quicker relief compared to oral medications. For example, in March 2023, Pfizer Inc., a US-based biotechnology company, introduced ZAVZPRET (zavegepant) Migraine Nasal Spray, approved by the FDA. This nasal spray uses zavegepant, a CGRP receptor antagonist, to block the calcitonin gene-related peptide (CGRP) pathway, providing swift and targeted relief from migraines. ZAVZPRET's fast-acting formulation offers relief within 15 minutes, making it a convenient choice for those seeking quick relief from severe migraine symptoms.

In October 2022, Pfizer Inc. acquired Biohaven Pharmaceutical Holding Company Ltd. for $11.6 billion. This acquisition aims to enhance Pfizer’s position in the neurology and pain management sectors by integrating Biohaven’s innovative migraine treatments and other neurological therapies. Biohaven Pharmaceutical Holding Company Ltd. specializes in treatments for acute migraines.

Major companies operating in the acute migraine treatment market are Pfizer Inc., Johnson And Johnson, Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Viatris Inc., Allergan plc, Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Endo International plc, Supernus Pharmaceuticals Inc., Collegium Pharmaceutical Inc., Upsher-Smith Laboratories LLC, BioDelivery Sciences International Inc., Axsome Therapeutics Inc., Impel NeuroPharma Inc., Currax Pharmaceuticals LLC, Satsuma Pharmaceuticals Inc.

North America was the largest region in the acute migraine treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute migraine treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the acute migraine treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Acute migraine treatments involve therapies aimed at providing immediate relief from migraine attacks by addressing symptoms such as intense headaches, nausea, and heightened sensitivity to light and sound. These treatments are designed to reduce the severity and duration of migraines, improving patient comfort and functionality during episodes.

The primary types of drugs used for acute migraine treatment include triptans, calcitonin gene-related peptide (CGRP) antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), beta-adrenergic blockers, ergot alkaloids, and others. Triptans are medications that specifically target serotonin 1B and 1D receptors, leading to vasoconstriction and reducing the release of inflammatory substances. They are considered specific treatments for migraines and are commonly used for acute relief. These medications can be administered orally, through injection, or by other methods and are available through various distribution channels, including hospital pharmacies, retail pharmacies, drug stores, and online platforms.

The acute migraine treatments market research report is one of a series of new reports that provides acute migraine treatments market statistics, including acute migraine treatments industry global market size, regional shares, competitors with an acute migraine treatments market share, detailed acute migraine treatments market segments, market trends, and opportunities, and any further data you may need to thrive in the acute migraine treatments industry. This acute migraine treatments research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The acute migraine treatment market consists of revenues earned by entities by providing emergency room (ER) services, headache centers, primary care physicians, and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute migraine treatment market also includes sales of acetaminophen, anti-nausea medications, CGRP antagonists, and transcranial magnetic stimulation (TMS) devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.